Michael S. Weiss - 28 May 2025 Form 4 Insider Report for Checkpoint Therapeutics, Inc. (CKPT)

Reporting relationship: Director
Issuer ticker: CKPT
Reported as of: 28 May 2025
Net transaction value: +$64,500
SEC form: 4
Accepted by SEC: 30 May 2025, 11:21:17 UTC
Prior SEC filing: 30 Jan 2025
Next SEC filing: 07 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ James F. Oliviero, Attorney-in-Fact

Key filing fact

Michael S. Weiss filed Form 4 for Checkpoint Therapeutics, Inc. (CKPT) on 30 May 2025.

Key facts

This page summarizes Michael S. Weiss's Form 4 filing for Checkpoint Therapeutics, Inc. (CKPT).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 30 May 2025, 11:21.

Change

Previous filing in this sequence was filed on 30 Jan 2025.
Current net transaction value: +$64,500.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001038977 Primary reporting owner

WEISS MICHAEL S

Relationship: Director
Address: 95 SAWYER ROAD, SUITE 110, WALTHAM
Signature: /s/ James F. Oliviero, Attorney-in-Fact
Signature date: 30 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CKPT transaction

COMMON STOCK

Award

Transaction value: $0
Shares: +12,195
Change %: +9.8%
Price: $0.000000
Shares after: 137,007
Date: 28 May 2025
Ownership: See Note 2
Footnotes: F1, F2

CKPT transaction

COMMON STOCK

Award

Transaction value: $64,500
Shares: +50,000
Change %: +36%
Price: $1.29
Shares after: 187,007
Date: 29 May 2025
Ownership: Direct

CKPT transaction

COMMON STOCK

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -187,007
Change %: -100%
Price
Shares after: 0
Date: 30 May 2025
Ownership: See Note 2
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Michael S. Weiss is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Includes restricted shares of Common Stock which vest over various time periods, subject to Mr. Weiss's continued service on the board.

Footnote F2

The shares were held by Hawkins BioVentures, LLC, of which Mr. Weiss is the sole member.

Footnote F3

Disposed of in connection with an offer made pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025 and as amended on April 14, 2025 (the "Merger Agreement"), in exchange for $4.10 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment ranging from $0.20 to $0.70 pursuant to certain milestone payments as defined in the Merger Agreement relating to the regulatory approval for cosibelimab in the European Union. The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application or equivalent application for cosibelimab receives a positive validation outcome by the European Medicines Agency.